| Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia H Alachkar, MBG Mutonga, KH Metzeler, N Fulton, G Malnassy, T Herold, ... Oncotarget 5 (23), 12371, 2014 | 68 | 2014 |
| Management of metastatic HER2-positive breast cancer: where are we and where do we go from here? CA Santa-Maria, L Nye, MB Mutonga, S Jain, WJ Gradishar Oncology (Williston Park, NY) 30 (2), 148-155, 2016 | 63 | 2016 |
| Cell-specific multifunctional processing of heterogeneous cell systems in a single laser pulse treatment EY Lukianova-Hleb, MBG Mutonga, DO Lapotko Acs Nano 6 (12), 10973-10981, 2012 | 60 | 2012 |
| Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia H Alachkar, N Fulton, B Sanford, G Malnassy, M Mutonga, RA Larson, ... The pharmacogenomics journal 17 (3), 274-279, 2017 | 51 | 2017 |
| Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection H Alachkar, M Mutonga, T Kato, S Kalluri, Y Kakuta, M Uemura, ... BMC nephrology 17, 1-9, 2016 | 34 | 2016 |
| T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia H Alachkar, M Mutonga, G Malnassy, JH Park, N Fulton, A Woods, L Meng, ... Oncotarget 6 (32), 33410, 2015 | 29 | 2015 |
| Targeting suppressor of variegation 3-9 homologue 2 (SUV39H2) in acute lymphoblastic leukemia (ALL) M Mutonga, K Tamura, G Malnassy, N Fulton, A de Albuquerque, ... Translational oncology 8 (5), 368-375, 2015 | 22 | 2015 |
| Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers CA Santa-Maria, M Kruse, P Raska, M Weiss, A Swoboda, MB Mutonga, ... Breast Cancer Research and Treatment 166, 179-184, 2017 | 7 | 2017 |
| Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer M Mutonga, S Speedy, A Rademaker, D Liu, R Uthe, S Jain, WJ Gradishar, ... Breast Cancer Research and Treatment 176, 95-100, 2019 | 3 | 2019 |
| Abstract No. 108 Does Clot Burden Affect Outcomes of Mechanical Pulmonary Thromboembolectomy? The Predictive Value of Qandali and Miller Index Scores in Patients with … A Fish, K Gruenwald, M Mutonga, J Moulton, M Andreca, R Gathigan, ... Journal of Vascular and Interventional Radiology 35 (3), S48, 2024 | | 2024 |
| 4: 03 PM Abstract No. 324 Survival comparison of patients undergoing elective transjugular intrahepatic portosystemic shunt creation with intermediate and high Model End Stage … M Joh, M Mutonga, E Li, A Riaz, S Mouli, L Kulik, R Lewandowski, ... Journal of Vascular and Interventional Radiology 31 (3), S147-S148, 2020 | | 2020 |
| 3: 36 PM Abstract No. 56 Predictive value of the change in portosystemic gradient on mortality after transjugular intrahepatic portosystemic shunt creation M Joh, M Mutonga, E Li, A Riaz, L Kulik, R Lewandowski, R Salem, ... Journal of Vascular and Interventional Radiology 31 (3), S28-S29, 2020 | | 2020 |
| 03: 18 PM Abstract No. 171 Predictors of survival after transjugular intrahepatic portosystemic shunt (TIPS) creation with covered stents M Joh, M Mutonga, E Li, S Mouli, A Riaz, L Kulik, R Lewandowski, ... Journal of Vascular and Interventional Radiology 30 (3), S78, 2019 | | 2019 |
| 03: 54 PM Abstract No. 175 Transjugular intrahepatic portosystemic shunt (TIPS) outcomes in orthotopic liver transplant versus native liver M Mutonga, M Joh, E Li, D Liu, A Riaz, L Kulik, R Lewandowski, ... Journal of Vascular and Interventional Radiology 30 (3), S80, 2019 | | 2019 |
| 4: 21 PM Abstract No. 291 MELD, MELD-Na, serum creatinine, and serum albumin as predictors of mortality after transjugular intrahepatic portosystemic shunt (TIPS) creation with … M Joh, E Li, M Mutonga, N Ali, A Riaz, L Kulik, R Lewandowski, ... Journal of Vascular and Interventional Radiology 29 (4), S125, 2018 | | 2018 |
| 2193: Targeting MELK in acute lymphoblastic leukemia, new therapeutic approach H Alachkar, M Mutonga, A de Albuquerque, R Deo, G Malnassy, ... Journal of Clinical and Translational Science 1 (S1), 58-59, 2017 | | 2017 |
| Relationship of pathological features and a 21 gene expression assay in young women with early breast cancer. MBG Mutonga, S Speedy, R Uthe, K Kindy, A Brownlee, S Jain, ... Journal of Clinical Oncology 35 (15_suppl), e12050-e12050, 2017 | | 2017 |
| High efficacy of T-LAK cell-originated protein kinase inhibitor in acute myeloid leukemia with FLT3-ITD mutation H Alachkar, M Mutonga, JH Park, G Malnassy, A Woods, G Raca, ... Cancer Research 75 (15_Supplement), 4381-4381, 2015 | | 2015 |
| PRECLINICAL EFFICACY OF T-LAK CELL-ORIGINATED PROTEIN KINASE INHIBITOR IN FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA. H Alachkar, M Mutonga, G Malnassy, J Park, A Woods, G Raca, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 97, S61-S62, 2015 | | 2015 |
Yusuke NakamuraJFCR, University of Chicago, University of Tokyo, RIKEN, Cancer Institute, Univ. of Utah, Osaka UnivVerified email at jfcr.or.jp
